3-(4-溴苯氧基)氮杂环丁烷-1-羧酸叔丁酯 | 960402-39-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 3-(4-溴苯氧基)氮杂环丁烷-1-羧酸叔丁酯
• 英文名称: tert-butyl 3-(4-bromophenoxy)azetidine-1-carboxylate
• CAS: 960402-39-5
• 化学式: C₁₄H₁₈BrNO₃
• 分子量: 328.206
• InChiKey: NBSUQHNPRXCCEP-UHFFFAOYSA-N

物化性质

• 沸点：
  388.3±32.0 °C(Predicted)
• 密度：
  1.397±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  38.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(4-溴苯氧基)氮杂环丁烷-1-羧酸叔丁酯 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 三甲基氯硅烷 、 potassium acetate 、 potassium carbonate 、 三乙胺 作用下， 以 1,4-二氧六环 、 2,2,2-三氟乙醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 49.0h， 生成 2-[3-[4-[4-[(E,3S)-4-hydroxy-3-[2-[(1S)-1-hydroxyethyl]imidazol-1-yl]but-1-enyl]phenyl]phenoxy]azetidin-1-yl]acetonitrile
  参考文献：
  名称：

  [EN] ANTIBACTERIAL COMPOUNDS
  [FR] COMPOSÉS ANTIBACTÉRIENS

  摘要：

  Provided herein are heterocyclic compounds and pharmaceutical compositions comprising said compounds that are useful for inhibiting the growth of gram-negative bacteria. The subject compounds and compositions are useful for the treatment of bacterial infections, such as pneumonia.

  公开号：

  WO2024036170A1
• 作为产物：
  描述：

  1-Boc-3-氮杂环丁酮 在 甲醇 、 4-二甲氨基吡啶 、 sodium tetrahydroborate 、 caesium carbonate 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 22.0h， 生成 3-(4-溴苯氧基)氮杂环丁烷-1-羧酸叔丁酯
  参考文献：
  名称：

  [EN] ANTIBACTERIAL COMPOUNDS
  [FR] COMPOSÉS ANTIBACTÉRIENS

  摘要：

  Provided herein are heterocyclic compounds and pharmaceutical compositions comprising said compounds that are useful for inhibiting the growth of gram-negative bacteria. The subject compounds and compositions are useful for the treatment of bacterial infections, such as pneumonia.

  公开号：

  WO2024036170A1

文献信息

• Design and synthesis of cyanamides as potent and selective N-acylethanolamine acid amidase inhibitors
  作者：Michael S. Malamas、Shrouq I. Farah、Manjunath Lamani、Dimitrios N. Pelekoudas、Nicholas Thomas Perry、Girija Rajarshi、Christina Yume Miyabe、Honrao Chandrashekhar、Jay West、Spiro Pavlopoulos、Alexandros Makriyannis

  DOI：10.1016/j.bmc.2019.115195

  日期：2020.1

  inflammation and pain. Thus, blocking the degradation of PEA with NAAA inhibitors results in augmentation of the PEA/PPAR-α signaling pathway and regulation of inflammatory and pain processes. We have prepared a new series of NAAA inhibitors exploring the azetidine-nitrile (cyanamide) pharmacophore that led to the discovery of highly potent and selective compounds. Key analogs demonstrated single-digit nanomolar

  N-酰基乙醇胺酸酰胺酶（NAAA）抑制代表了一种激动人心的新颖方法，用于治疗炎症和疼痛。NAAA是半胱氨酸酰胺酶，可优先水解内源性生物脂质棕榈酰乙醇酰胺（PEA）和油酰乙醇酰胺（OEA）。PEA是核过氧化物酶体增殖物激活受体-α（PPAR-α）的内源性激动剂，PPAR-α是炎症和疼痛的关键调节剂。因此，用NAAA抑制剂阻止PEA的降解会导致PEA /PPAR-α信号传导途径的增强以及炎症和疼痛过程的调节。我们准备了一系列新的NAAA抑制剂，用于研究氮杂环丁烷-腈（氰胺）药效团，从而发现了高效且选择性强的化合物。关键类似物显示出hNAAA的一位数纳摩尔效价，并显示> 对丝氨酸水解酶FAAH，MGL和ABHD6和半胱氨酸蛋白酶组织蛋白酶K的选择性是100倍。此外，我们已经确定了有效的和选择性的双重NAAA-FAAH抑制剂来研究两种不同的抗炎分子途径PEA / PPAR之间的潜在协同作用-α抗炎
• [EN] SUBSTITUTED AZETIDINE DERIVATIVES AS TAAR LIGANDS<br/>[FR] DÉRIVÉS D'AZÉTIDINE SUBSTITUÉS EN TANT QUE LIGANDS DE TAAR
  申请人：HOFFMANN LA ROCHE

  公开号：WO2016030310A1

  公开（公告）日：2016-03-03

  The present invention relates to a compound of formula I wherein R1 is hydrogen, methoxy or fluoro; R2/R2' are independently from each other hydrogen, methoxy or fluoro; R3/R4 are independently from each other hydrogen or halogen; R is hydrogen or fluoro; L1 is -CH2-, -NR'-, -0-, -S-, CF2- or CH=; R' is hydrogen or lower alkyl; L2 is a bond, -C(0)NH-, -NH-, -CH2NHC(O)-, -NHC(O)- or -NHC(0)NH-; R is hydrogen, halogen, lower alkoxy, cyano or is phenyl optionally substituted by one or more substituents, selected from halogen, lower alkyl substituted by halogen or lower alkoxy, or is a five or six membered heteroaryl, selected from pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl or pyrazolyl, which heteroaryls are optionally substituted by one or more substituents, selected from halogen, lower alkyl, lower alkoxy, cyano, cycloalkyl, lower alkyl substituted by halogen, lower alkoxy substituted by halogen or by phenyl substituted by halogen; N is a ring nitrogen atom in position 1 or 2; or to a pharmaceutically suitable acid addition salt thereof. The compounds of formulas I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1 and may be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

  本发明涉及一种具有以下式I的化合物，其中R1是氢、甲氧基或氟；R2/R2'分别独立地是氢、甲氧基或氟；R3/R4分别独立地是氢或卤素；R是氢或氟；L1是-CH2-、-NR'-、-O-、-S-、CF2-或CH=；R'是氢或较低的烷基；L2是键、-C(0)NH-、-NH-、- NHC(O)-、-NHC(O)-或-NHC(0)NH-；R是氢、卤素、较低的烷氧基、氰基或是苯环，可以选择性地被一个或多个取代基取代，所述取代基选自卤素、被卤素或较低的烷氧基取代的较低烷基、或是被卤素取代的苯环，或是一个五元或六元杂环芳基，选自吡啶基、嘧啶基、吡嗪基、吡啶嗪基或吡唑基，这些杂环芳基可以选择性地被一个或多个取代基取代，所述取代基选自卤素、较低的烷基、较低的烷氧基、氰基、环烷基、被卤素取代的较低烷基、被卤素取代的较低烷氧基或被卤素取代的苯基；N是1或2位置的环氮原子；或其药学上适宜的酸盐。式I的化合物对痕量胺相关受体(TAARs)具有良好的亲和力，特别是对TAAR1，可用于治疗抑郁症、焦虑症、双相情感障碍、注意缺陷多动障碍(ADHD)、与压力有关的障碍、如精神分裂症、帕金森病等神经疾病、阿尔茨海默病等神经退行性疾病、癫痫、偏头痛、高血压、物质滥用和代谢障碍，如进食障碍、糖尿病、糖尿病并发症、肥胖症、血脂异常、能量消耗和吸收障碍、体温稳态障碍、睡眠和昼夜节律障碍以及心血管疾病的治疗。
• [EN] 1, 4-SUBSTITUTED PIPERIDINE DERIVATIVES<br/>[FR] DÉRIVÉS DE PIPÉRIDINE 1,4-SUBSTITUÉS
  申请人：CEPHALON INC

  公开号：WO2016205633A1

  公开（公告）日：2016-12-22

  Described herein are 1,4-substituted piperidine compounds according to Formula (I) that have demonstrated activity as fatty acid synthase inhibitors. Also described herein are pharmaceutical compositions containing the described 1,4-substituted piperidine compounds, and methods of treating diseases mediated by fatty acid synthase, by administering one or more of the compounds or pharmaceutical formulations described herein. Also described herein are methods of synthesizing the compounds described, including the described 1,4-substituted piperidine compounds and synthetic intermediates useful in those syntheses.

  本文描述了按照式（I）的1,4-取代哌啶化合物，这些化合物已经表现出作为脂肪酸合成酶抑制剂的活性。本文还描述了含有所述1,4-取代哌啶化合物的药物组合物，以及通过给予所述化合物或药物配方中的一个或多个来治疗由脂肪酸合成酶介导的疾病的方法。本文还描述了合成所述化合物的方法，包括所述的1,4-取代哌啶化合物和在这些合成中有用的合成中间体。
• INDOLE AND INDAZOLE COMPOUNDS THAT ACTIVATE AMPK
  申请人：PFIZER INC.

  公开号：US20130267493A1

  公开（公告）日：2013-10-10

  The present invention relates to indole and indazole compounds of Formula (I) that activate 5′ adenosine monophosphate-activated protein kinase (AMPK). The invention also encompasses pharmaceutical compositions containing these compounds and methods for treating or preventing diseases, conditions, or disorders ameliorated by activation of AMPK.

  本发明涉及激活5'-腺苷单磷酸活化蛋白激酶（AMPK）的吲哚和吲唑化合物的化学式（I）。该发明还包括含有这些化合物的药物组合物以及治疗或预防通过激活AMPK改善的疾病、症状或疾病的方法。
• NOVEL MCH RECEPTOR ANTAGONISTS
  申请人：Arnold Macklin Brian

  公开号：US20090093456A1

  公开（公告）日：2009-04-09

  The present invention relates to a melanin concentrating hormone antagonist compound of formula (1): wherein R 1 , R a , R b , R 2 , L 1 , R 3 , R 4 and R 5 are as defined, or a pharmaceutically acceptable salt, enantiomer, diastereomer or mixture of diasteromers thereof useful in the treatment, obesity and related diseases.

  本发明涉及一种公式（1）的黑色素浓集激素拮抗剂化合物：其中R1、Ra、Rb、R2、L1、R3、R4和R5如定义所述，或其药学上可接受的盐、对映体、非对映体或其混合物，可用于治疗肥胖和相关疾病。